Suppr超能文献

瓜美林与胰凝乳蛋白酶复合物的晶体结构及弹性蛋白酶特异性抑制剂的研发。

The crystal structure of guamerin in complex with chymotrypsin and the development of an elastase-specific inhibitor.

作者信息

Kim Hun, Chu Trang Thi Thu, Kim Dong Young, Kim Dong Ryoung, Nguyen Chi My Thi, Choi Jongkeun, Lee Jae-Rin, Hahn Myong-Joon, Kim Kyeong Kyu

机构信息

Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea.

出版信息

J Mol Biol. 2008 Feb 8;376(1):184-92. doi: 10.1016/j.jmb.2007.11.089. Epub 2007 Dec 4.

Abstract

Guamerin, a canonical serine protease inhibitor from Hirudo nipponia, was identified as an elastase-specific inhibitor and has potential application in various diseases caused by elevated elastase concentration. However, the application of guamerin is limited because it also shows inhibitory activity against other proteases. To improve the selectivity of guamerin as an elastase inhibitor, it is essential to understand the binding mode of the inhibitor to elastase and to other proteases. For this purpose, we determined the crystal structure of guamerin in complex with chymotrypsin at 2.5 A resolution. The binding mode of guamerin on elastase was explored from the model structure of guamerin/elastase. Guamerin binds to the hydrophobic pocket of the protease in a substrate-like manner using its binding loop. In order to improve the binding selectivity of guamerin to elastase, several residues in the binding loop were mutated and the inhibitory activities of the mutants against elastase and chymotrypsin were monitored. The substitution of the Met36 residue for Ala in the P1 site increased the inhibitory activity against elastase up to 14-fold, while the same mutant showed 7-fold decreased activity against chymotrypsin compared to the wild-type guamerin. Furthermore, the M36A guamerin mutant more effectively protected endothelial cells against cell damage caused by elastase than the wild-type guamerin.

摘要

瓜美宁是一种来自日本医蛭的典型丝氨酸蛋白酶抑制剂,被鉴定为弹性蛋白酶特异性抑制剂,在由弹性蛋白酶浓度升高引起的各种疾病中具有潜在应用价值。然而,瓜美宁的应用受到限制,因为它对其他蛋白酶也表现出抑制活性。为了提高瓜美宁作为弹性蛋白酶抑制剂的选择性,了解该抑制剂与弹性蛋白酶及其他蛋白酶的结合模式至关重要。为此,我们测定了瓜美宁与胰凝乳蛋白酶复合物的晶体结构,分辨率为2.5埃。从瓜美宁/弹性蛋白酶的模型结构中探索了瓜美宁在弹性蛋白酶上的结合模式。瓜美宁利用其结合环以类似底物的方式与蛋白酶的疏水口袋结合。为了提高瓜美宁对弹性蛋白酶的结合选择性,对结合环中的几个残基进行了突变,并监测了突变体对弹性蛋白酶和胰凝乳蛋白酶的抑制活性。在P1位点将Met36残基替换为Ala,使对弹性蛋白酶的抑制活性提高了14倍,而与野生型瓜美宁相比,相同突变体对胰凝乳蛋白酶的活性降低了7倍。此外,与野生型瓜美宁相比,M36A瓜美宁突变体更有效地保护内皮细胞免受弹性蛋白酶引起的细胞损伤。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验